GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PharmaCyte Biotech PMCB · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.41

+13.06%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About PharmaCyte Biotech

From its filings with the US Securities and Exchange Commission

SEC filings

PharmaCyte Biotech is based in Las Vegas, Nevada and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker PMCB. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 30 April 2026, it reported revenue of $0 and a net loss of $19.4m. At that date it held total assets of $46.8m and shareholders' equity of $33.3m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
11 Sept 2003
Employees
2
Head office
3960 HOWARD HUGHES PARKWAY, LAS VEGAS, NV, 89169
Incorporated in
NV
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Joshua SilvermanInterim Chairman of the Board, Interim Chief Executive Officer and Interim President, since 2022$687,923
  • Mr. Carlos TrujilloChief Financial Officer, since 2017$536,562
  • Dr. Michael AbecassisIndependent Director$296,000
  • Mr. Jonathan SchechterIndependent Director$290,000
  • Mr. Wayne WalkerIndependent Director$265,000
  • Mr. Robert WeinsteinIndependent Director$290,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • PharmaCyte Biotech Inc employs 4 full-time employees in Laguna Hills, California.
  • Cell-in-a-Box technology enables targeted drug delivery for cancer and diabetes treatments.
  • The company focuses on clinical stage biotechnology with a platform for cancer and diabetes therapies.

Weaknesses

  • PharmaCyte Biotech has only 2 employees as stated in the facts.
  • The company's IPO was on 11 September 2003, indicating a long history without significant growth.
  • The business description mentions only 4 full-time employees despite the stated 2 employees.

Opportunities

  • PharmaCyte Biotech's Cell-in-a-Box technology offers potential for advanced pancreatic cancer treatments.
  • The company is developing therapies for Type I and insulin-dependent Type II diabetes using encapsulated cells.
  • Expanding the Cell-in-a-Box platform could address multiple cancer types and diabetes segments.

Threats

  • PharmaCyte Biotech faces competition in the Health Care sector for cancer and diabetes treatments.
  • The biotechnology industry has high development costs and regulatory hurdles for new therapies.
  • The company's small team size of 2 employees may limit its ability to scale rapidly.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.